Overview

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen

Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter, non-profit. The hypothesis of the present study is that bictegravir is associated with a lower incidence and severity of neuropsychiatric symptoms than dolutegravir.
Phase:
Phase 3
Details
Lead Sponsor:
Azienda Ospedaliera Universitaria Senese
Collaborators:
Azienda Ospedaliera San Paolo
Catholic University of the Sacred Heart
Ospedale Amedeo di Savoia
Ospedale Policlinico San Martino
Treatments:
Abacavir
Dideoxynucleosides
Dolutegravir
Emtricitabine
Emtricitabine tenofovir alafenamide
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Lamivudine
Tenofovir
Triumeq